As recently reported in the media, The Children’s Hospital of Philadelphia is conducting an FDA-funded study to determine if components of PEG 3350, contained in certain over-the-counter medications commonly prescribed by physicians to treat constipation in children, are absorbed into children’s blood. While PEG 3350 is currently thought to be poorly absorbed into the blood, the FDA has received reports from parents who are concerned that it has caused neurobehavioral symptoms in their children.
At this time, we are not aware of any scientific study indicating that PEG 3350 is dangerous or causes neurobehavioral symptoms. Our study seeks to determine if PEG 3350 is absorbed into the blood, and if so, whether it could lead to the reported adverse effects.
Researchers in CHOP’s Division of Gastroenterology who will be conducting the study have not begun enrolling children, but once enrollment begins, an announcement will be made. Our researchers are very interested in working with the FDA to assess the safety of this medicine in children.
Parents should talk to their child’s pediatrician regarding use of products containing PEG 3350 and any concerns they may have.